RESUMO
Bone marrow (BM) examination is included in the diagnostic algorithm of fever of unknown origin (FUO), although its role is not clearly determined. The purpose of this study was to assess the role of BM studies in patients with FUO. We retrospectively reviewed 45 consecutive patients (25% human immunodeficiency virus-positive) with FUO who underwent a BM study in the University Hospital of Salamanca from 2000 to 2010. We analysed the diagnostic role of BM smears, multiparameter flow cytometry analysis, histology and microbiological cultures. Five patients (11%) were finally diagnosed by BM study (three had an infectious disease and two were found to have haematological malignancies), all of whom were immunocompetent patients. Histology was the most useful study (diagnosis was obtained in 4/5 patients), while BM cultures did not establish the final diagnosis in any patient. Flow cytometry established the diagnosis in one patient, although this patient was also diagnosed by histology. In conclusion, BM study is useful for establishing the aetiology of FUO. BM biopsy for histological examination should be always mandatory if a BM examination is performed.
Assuntos
Exame de Medula Óssea , Febre de Causa Desconhecida/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Medula Óssea/patologia , Exame de Medula Óssea/estatística & dados numéricos , Células Cultivadas , Criança , Pré-Escolar , Feminino , Febre de Causa Desconhecida/etiologia , Febre de Causa Desconhecida/patologia , Infecções por HIV/complicações , Infecções por HIV/patologia , Humanos , Lactente , Leishmaniose/complicações , Leishmaniose/diagnóstico , Leishmaniose/patologia , Leucemia de Células Pilosas/complicações , Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/patologia , Linfo-Histiocitose Hemofagocítica/complicações , Linfo-Histiocitose Hemofagocítica/diagnóstico , Linfo-Histiocitose Hemofagocítica/patologia , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tuberculose/complicações , Tuberculose/diagnóstico , Tuberculose/patologia , Adulto JovemRESUMO
The aim of this work was to review the current recommendations for staging and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in routine clinical practice after chemotherapy and/or stem cell transplantation. A five-point scale (5-PS) from the First International Workshop on PET in Lymphoma in Deauville, France, in 2009, was recommended as the standard tool to score imaging to assess treatment response in patients with lymphoma using 18F-Fluorodeoxyglucose (FDG) PET/CT. Following the recommendations of the 11th and 12th International Conferences on Malignant Lymphoma held in Lugano (Switzerland), in 2011 and 2013, respectively, a consensus (the so-called Lugano Classification) was reached regarding the use of PET/CT for staging and response assessment in FDG-avid lymphomas. As a result, 18F-FDG PET/CT was formally incorporated into standard staging for FDG-avid lymphomas. A bone marrow biopsy is no longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. PET/CT will be used to assess response in FDG-avid histologies using the 5-point scale. The recent introduction of biological agents with immune mechanisms requires flexibility in interpretations of the Lugano criteria due to tumour flare or a pseudo-progression effect produced by these agents. Provisional criteria have been proposed (Lymphoma Response to Immunomodulatory Therapy Criteria) with the introduction of the term 'Indeterminate Response' in order to identify this phenomenon until confirmed as flare/pseudoprogression or true progression. All these recommendations will improve evaluations of patients with lymphoma, and allow comparison of results from clinical practice and trials.
Assuntos
Fluordesoxiglucose F18 , Doença de Hodgkin/diagnóstico por imagem , Linfoma não Hodgkin/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Compostos Radiofarmacêuticos , Doença de Hodgkin/terapia , Humanos , Linfoma não Hodgkin/terapia , Guias de Prática Clínica como AssuntoRESUMO
The safety and efficacy of a 4-day myeloablative conditioning (MAC) regimen consisting of Bu 3.2 mg/kg and fludarabine 40 mg/m(2)/day for HLA-identical sibling allogeneic hematopoietic cell transplantation (HCT) in myeloid malignancies was investigated in 133 patients (median age, 47 years; range 19-74 years) with de novo AML (60%), secondary AML (20%) or myelodysplastic syndrome (20%). All patients engrafted. Hepatic veno-occlusive disease occurred in five patients (4%), and severe toxicities, mostly mucositis, occurred in twenty-three (17%) patients. The non-relapse mortality (NRM) at 100 days was 1.5%. The incidences of acute GVHD grade 2-4 and grade 3-4 were 32 and 13%, respectively. At a median follow-up of 38 months, the cumulative incidence of chronic GVHD was 67%. The relapse incidence was 30% (27 and 31%, respectively, in patients with early- and late-stage disease), and the overall NRM was 15%. The actuarial 4-year disease-free survival (DFS) and overall survival (OS) were 54 and 62%, respectively. Patients aged <50 years had better outcomes compared with older patients (DFS 64 vs 42%, P=0.006; OS 73 vs 47%, P<0.001, respectively).
Assuntos
Bussulfano/administração & dosagem , Transplante de Células-Tronco Hematopoéticas/métodos , Leucemia Mieloide Aguda/terapia , Agonistas Mieloablativos/toxicidade , Síndromes Mielodisplásicas/terapia , Condicionamento Pré-Transplante/métodos , Vidarabina/análogos & derivados , Adulto , Idoso , Bussulfano/toxicidade , Doença Enxerto-Hospedeiro/etiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/mortalidade , Hepatopatia Veno-Oclusiva/induzido quimicamente , Hepatopatia Veno-Oclusiva/etiologia , Histocompatibilidade/imunologia , Humanos , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/mortalidade , Pessoa de Meia-Idade , Mucosite/induzido quimicamente , Mucosite/etiologia , Agonistas Mieloablativos/uso terapêutico , Síndromes Mielodisplásicas/complicações , Síndromes Mielodisplásicas/mortalidade , Recidiva , Análise de Sobrevida , Condicionamento Pré-Transplante/mortalidade , Vidarabina/administração & dosagem , Vidarabina/toxicidade , Adulto JovemRESUMO
The impact of donor age in patients with acute myeloid leukemia and myelodysplastic syndrome who underwent allogeneic hematopoietic stem cell transplant (HSCT) remains unclear. In the current study, we evaluate 179 consecutive patients who received an HSCT, from January 2000 to January 2013, in our Institution. Most of the HSCT (91%) were HLA-matched. Patient and donor median age were 51 years (18-69) and 47 years (12-75) respectively, and 81 donors (45%) were older than 50 years. The median follow-up was 38 months (range 1-138), Kaplan-Meier estimated 3-year overall survival (OS) was 63% and disease free survival (DFS) was 56%. Interestingly, patients who received an HSCT from a donor older age (>50 y) showed a poorer OS (51% vs 73%; p=0.01), as well as a higher TRM (20% vs 8%; p=0.038) and higher relapse rate (28% vs 39%; p=0.03). In a stratified subanalysis, 3-year estimated OS was significantly lower among patients undergoing an HSCT from >50 years sibling donors compared to those receiving an HSCT from <50 years unrelated donor (54% vs 72%; p<0.001). In summary, we can conclude that receiving an HSCT from a donor over 50 years old is associated with poorer outcome in patients diagnosed with MDS and AML, and this information may be incorporated into the complex process of donor selection.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda/terapia , Síndromes Mielodisplásicas/terapia , Doadores não Relacionados/estatística & dados numéricos , Adolescente , Adulto , Fatores Etários , Idoso , Criança , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Transplante de Células-Tronco Hematopoéticas/estatística & dados numéricos , Humanos , Leucemia Mieloide Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/mortalidade , Análise de Sobrevida , Transplante Homólogo , Resultado do Tratamento , Adulto JovemAssuntos
Benzoatos/administração & dosagem , Transplante de Células-Tronco Hematopoéticas , Hidrazinas/administração & dosagem , Pirazóis/administração & dosagem , Trombocitopenia/tratamento farmacológico , Adulto , Idoso , Aloenxertos , Benzoatos/efeitos adversos , Feminino , Humanos , Hidrazinas/efeitos adversos , Masculino , Pessoa de Meia-Idade , Pirazóis/efeitos adversos , Estudos Retrospectivos , Trombocitopenia/sangue , Trombocitopenia/etiologiaAssuntos
Anticorpos Monoclonais/uso terapêutico , Transplante de Células-Tronco Hematopoéticas/métodos , Leucemia Linfocítica Crônica de Células B/terapia , Condicionamento Pré-Transplante/métodos , Adulto , Anticorpos Monoclonais Humanizados , Antígenos CD20/análise , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Humanos , Leucemia Linfocítica Crônica de Células B/mortalidade , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Recidiva , Fatores de Risco , Prevenção Secundária , Análise de Sobrevida , Condicionamento Pré-Transplante/mortalidade , Transplante Homólogo , Resultado do TratamentoRESUMO
OBJECTIVES: To discover the cooking habits of school students' families and the full nutritional picture of the school population of Huercal de Almería. To gather the views and attitudes of school students and mothers on the low amount of milk and vegetables consumed. DESIGN: Crossover, descriptive and technical study with focus group. SETTING: Rural area. METHODS: The study had three stages: 1. A questionnaire for all the school students on their food habits (675). 2. A sample of 101 students aged between 4 and 6 and between 10 and 14 was chosen for the nutritional study. Students at nutritional risk in 1996 (95% CI; p.q = 0.25). Intake was analysed through the "memory of 24 hours", measurement of physical details and biochemical determinations. 3. We gathered views and attitudes by the focus group technique in 1997, with 60 girls between 10 and 14 and mothers in 6 groups. MAIN RESULTS: Habits: the most commonly eaten meat was chicken, followed by pork, stewed if possible. Blue and fried fish, full-cream milk, white bread, fresh green vegetables and olive oil. Nutritional study: the students' weight and height were above average. Denutrition was rare: we found three students with a percentile less than three. There was tendency to overweight in both sexes, with cholesterol levels above 200 mgr in the 4-6 group. Hyper-protein and hyper-fatty diet. The Ca/P quotient was P < 1, especially in the 10-14 girls. Consumption of pulses, fibre, cereals and root vegetables was less than the recommended amounts. Micronutrients were sufficient except for less iron in 10 to 14 girls. Focal groups: the four groups of girls coincided in rejection of green vegetables, repeating to some extent habits acquired in their families. Usually vegetables are rejected without having been tried, due to smell, texture and look. Positive knowledge about milk and vegetables was not shown in practice. CONCLUSIONS: Hyper-protein and hyper-fat diet with high cholesterol levels, weight and height above the average and tendency to overweight. They all rejected green vegetables. They repeated family eating habits.